Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 6/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5965486 | 0.92 | MCHR1 (0.40) | DRD3MCHR1TMEM97SLC6A4HRH3 | |
| SCHEMBL5965546 | 0.88 | MGLL (0.41) | MGLLDRD3TBXA2R | |
| SCHEMBL5965429 | 0.86 | HRH3 (0.39) | DRD3MCHR1SLC6A4HRH3HRH2 | |
| SCHEMBL5965542 | 0.86 | SLC6A4 (0.41) | DRD3MCHR1SLC6A4HRH3HRH2 | |
| SCHEMBL7242638 | 0.84 | MGLL (0.39) | MGLLDRD3TBXA2RMCHR1TMEM97 | |
| SCHEMBL5965518 | 0.82 | HRH3 (0.39) | DRD3MCHR1SLC6A4HRH3HRH2 | |
| SCHEMBL5965689 | 0.82 | SLC6A4 (0.39) | SLC6A4HRH3 | |
| SCHEMBL6095424 | 0.80 | POLB (0.41) | DRD3MCHR1TMEM97SLC6A4HRH3 | |
| SCHEMBL7250836 | 0.80 | MGLL (0.39) | MGLLDRD3TBXA2RSLC6A4HRH3 | |
| SCHEMBL5965641 | 0.79 | POLB (0.42) | DRD3MCHR1SLC6A4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012074-B2 | 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-03-14 | — | — | US | disclosed |
| US-20040023971-A1 | 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023971-A1 | 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, RYR2 | MGLL 3751/4885DRD3 224/4885TBXA2R 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.